XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Feb. 28, 2025
Feb. 29, 2024
Feb. 28, 2025
Feb. 29, 2024
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)        
Revenue $ 174,000 $ 145,000 $ 357,923 $ 296,278
Cost of goods sold 0 0 2,720 4,822
Gross profit 174,000 145,000 355,203 291,456
Operating expenses        
Research and development 1,685,916 245,779 3,639,136 820,270
General and administrative 1,239,096 567,226 2,157,786 1,278,333
Total operating expenses 2,925,012 813,005 5,796,922 2,098,603
Loss from operations (2,751,012) (668,005) (5,441,719) (1,807,147)
Other income (loss)        
Interest income (expense) 0 (1) 11 7,318
Unrealized gain (loss) on marketable securities 34,040 15,273 18,108 (37,942)
Total other income (loss) 34,040 15,272 18,119 (30,624)
Net loss (2,716,972) (652,733) (5,423,600) (1,837,771)
Less: Net loss attributable to non-controlling interest (3,760) (3,194) (6,689) (8,909)
Net loss attributable to Lexaria shareholders (2,713,212) (649,539) (5,416,911) (1,828,862)
Other comprehensive income        
Foreign currency translation adjustment (95,255) (24,998) (98,430) (20,626)
Total comprehensive loss $ (2,808,467) $ (674,537) $ (5,515,341) $ (1,849,488)
Basic and diluted loss per share $ (0.15) $ (0.06) $ (0.32) $ (0.18)
Weighted average number of common shares outstanding        
- Basic and diluted 17,511,908 10,765,143 17,065,084 9,970,489